Dr. Atul Matta, M.B.B.S Internal Medicine - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 200 Blossom St, Webster, TX 77598 Phone: 832-632-6500 |
Luigi Terminella, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 N Kobayashi Ste 208, Webster, TX 77598 Phone: 281-724-8180 Fax: 281-336-1171 |
Majd Alnas, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 199 Blossom St Ste D, Webster, TX 77598 Phone: 832-240-4566 Fax: 832-240-4630 |
Maaz Abbasi, M.D. Internal Medicine - Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 N Kobayashi, Suite A, Webster, TX 77598 Phone: 281-724-1860 Fax: 281-724-1861 |
News Archive
In October 2008 the province's Health Quality Council released its first "state of health care quality" report, called Quality Insight. Key messages in that inaugural report were that limited access to timely data and the absence of an electronic health record were making it hard for HQC, health providers, and system leaders to improve health care for Saskatchewan patients.
Gene editing has been a much sought after and controversial technology. Last month, part of the World Health Organization called for an international registry to track all research into editing the human genome.
Betty Heiman, Founder and President of Transparent Health Network, praised the announcement made today that the FTC and State enforcement officials will crackdown on scammers who target uninsured, unemployed and uninsurable individuals by peddling fraudulent medical discount plans. These plans, according to government officials, are marketed as health insurance but possess few or none of the features either of insurance or of actual plans.
A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules. The reaction they have come up with should enable chemists to synthesize new varieties of a whole subclass of organic compounds called nitrogen-containing heterocycles, thus opening up new avenues for the development of novel pharmaceuticals and natural products ranging from chemotherapeutic compounds to bioactive plant materials such as morphine.
Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board ("DSMB") has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer ("HEAT study") and has recommended that Celsion continue to enroll patients in the trial.
› Verified 4 days ago